Emergent Biosolutions Inc

NYSE:EBS   3:59:57 PM EDT
63.71
-2.19 (-3.32%)
4:00:00 PM EDT: $63.83 +0.12 (+0.19%)
Products, Business Deals

Emergent BioSolutions - Second Option Exercise Was Made Under Emergent's Existing 10-Year Contract Awarded By ASPR On August 30, 2019

Published: 07/14/2021 10:43 GMT
Emergent Biosolutions Inc (EBS) - Emergent Biosolutions - Second Option Exercise Was Made Under Emergent's Existing 10-year Contract Awarded by Aspr on August 30, 2019.
Emergent Biosolutions - Entire Amount is Expected to Be Delivered in Fiscal Year 2021.
Emergent Biosolutions Inc - Second Option Exercise is Valued at Approximately $182.2 Million.
Emergent Biosolutions - Period of Performance Under Second Option Exercise Requires Emergent to Deliver Doses of Acam2000 Into Sns by December 31.
Emergent Biosolutions - on July 13, Co Through Its Unit Emergent Product Development Gaithersburg Received a Contract Modification From Office of Aspr.
Further Company Coverage: Ebsn ((reuters.
Briefs@thomsonreuters.
Com;)).